A476060 Stock Overview

Engages in the research and development of anti-cancer therapy in South Korea. More details

A476060 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Onconic Therapeutics Inc. Competitors

Cytogen

KOSDAQ:A217330

₩126.4b

Helixmith

KOSDAQ:A084990

₩122.9b

Cellid

KOSDAQ:A299660

₩117.1b

MedPacto

KOSDAQ:A235980

₩148.6b

Price History & Performance

Summary of share price highs, lows and changes for Onconic Therapeutics
Historical stock prices
Current Share Price	₩21,400.00
52 Week High	₩26,100.00
52 Week Low	₩16,200.00
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	64.62%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	A476060	KR Biotechs	KR Market
7D	n/a	0.1%	-1.6%
1Y	n/a	16.9%	-9.1%

Return vs Industry: Insufficient data to determine how A476060 performed against the KR Biotechs industry.

Return vs Market: Insufficient data to determine how A476060 performed against the KR Market.

Price Volatility

Is A476060's price volatile compared to industry and market?
A476060 volatility
A476060 Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.7%
Market Average Movement	6.6%
10% most volatile stocks in KR Market	12.6%
10% least volatile stocks in KR Market	3.3%

Stable Share Price: A476060's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: Insufficient data to determine A476060's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2020	n/a	John Kim	onconic.co.kr

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer.

Onconic Therapeutics Inc. Fundamentals Summary

How do Onconic Therapeutics's earnings and revenue compare to its market cap?
A476060 fundamental statistics
Market cap	₩231.20b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A476060 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A476060 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A476060 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 19:22
End of Day Share Price	2024/12/20 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Onconic Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution